Loading...

John Keltner

TitlePROF EMERITUS(WOS)
InstitutionUniversity of California Davis
DepartmentMED: OPHTHALMOLOGY
AddressACC/UCDMC
CA 95817
Phone916-734-6073
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Cello KE, Keltner J, Johnson CA, Wall M. Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial. J Neuroophthalmol. 2016 Mar; 36(1):6-12. PMID: 26618282.
      View in: PubMed
    2. Wall M, Johnson CA, Cello KE, Zamba KD, McDermott MP, Keltner J. Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Invest Ophthalmol Vis Sci. 2016 Mar; 57(3):805-12. PMID: 26934136; PMCID: PMC4777274.
    3. Chin EK, Almeida DR, Lam KV, Keltner J, Thirkill CE. Positive Auto-Antibody Activity With Retina and Optic Nerve in Smokers and Non-Smokers: The Controversy Continues. Ophthalmic Surg Lasers Imaging Retina. 2015 Nov-Dec; 46(10):1068-70. PMID: 26599255.
      View in: PubMed
    4. Malvar J, Vaida F, Sanders CF, Atkinson JH, Bohannon W, Keltner J, Robinson-Papp J, Simpson DM, Marra CM, Clifford DB, Gelman B, Fan J, Grant I, Ellis RJ. Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy. Pain. 2015 Apr; 156(4):731-9. PMID: 25659067.
      View in: PubMed
    5. Lee AG, Keltner J. Fellowship training in neuro-ophthalmology in the United States. J Neuroophthalmol. 2015 Mar; 35(1):1-2. PMID: 25546237.
      View in: PubMed
    6. Rizzo JL, Lam KV, Wall M, Wilson MD, Keltner J. Perimetry, retinal nerve fiber layer thickness and papilledema grade after cerebrospinal fluid shunting in patients with idiopathic intracranial hypertension. J Neuroophthalmol. 2015 Mar; 35(1):22-5. PMID: 25295682; PMCID: PMC5017247.
    7. Auinger P, Durbin M, Feldon S, Garvin M, Kardon R, Keltner J, Kupersmith M, Sibony P, Plumb K, Wang JK, Werner JS. Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part I: quality control, comparisons, and variability. Invest Ophthalmol Vis Sci. 2014 Nov 04; 55(12):8180-8. PMID: 25370510; PMCID: PMC4266084.
    8. Auinger P, Durbin M, Feldon S, Garvin M, Kardon R, Keltner J, Kupersmith MJ, Sibony P, Plumb K, Wang JK, Werner JS. Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part II: correlations and relationship to clinical features. Invest Ophthalmol Vis Sci. 2014 Nov 04; 55(12):8173-9. PMID: 25370513; PMCID: PMC4266073.
    9. Friedman DI, McDermott MP, Kieburtz K, Kupersmith M, Stoutenburg A, Keltner J, Feldon SE, Schron E, Corbett JJ, Wall M. The idiopathic intracranial hypertension treatment trial: design considerations and methods. J Neuroophthalmol. 2014 Jun; 34(2):107-17. PMID: 24739993.
      View in: PubMed
    10. Wall M, Kupersmith MJ, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner J, Schron EB, McDermott MP. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol. 2014 Jun; 71(6):693-701. PMID: 24756302; PMCID: PMC4351808.
    11. Keltner J, Johnson CA, Cello KE, Wall M. Baseline visual field findings in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Invest Ophthalmol Vis Sci. 2014 Apr 29; 55(5):3200-7. PMID: 24781936; PMCID: PMC4031894.
    12. Winges KM, Werner JS, Harvey DJ, Cello KE, Durbin MK, Balcer LJ, Calabresi PA, Keltner J. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis. J Neuroophthalmol. 2013 Dec; 33(4):322-9. PMID: 24051419; PMCID: PMC3959779.
    13. Slamovits TL, Posner JB, Reidy DL, Thirkill CE, Keltner J. Pancreatic neuroendocrine paraneoplastic optic neuropathy: confirmation with antibody to optic nerve and hepatic metastasis. J Neuroophthalmol. 2013 Mar; 33(1):21-5. PMID: 22926698.
      View in: PubMed
    14. Krispel CM, Keltner J, Smith W, Chu DG, Ali MR. Undiagnosed papilledema in a morbidly obese patient population: a prospective study. J Neuroophthalmol. 2011 Dec; 31(4):310-5. PMID: 21799447.
      View in: PubMed
    15. Watson GM, Keltner J, Chin EK, Harvey D, Nguyen A, Park SS. Comparison of retinal nerve fiber layer and central macular thickness measurements among five different optical coherence tomography instruments in patients with multiple sclerosis and optic neuritis. J Neuroophthalmol. 2011 Jun; 31(2):110-6. PMID: 21131852.
      View in: PubMed
    16. Artes PH, Chauhan BC, Keltner J, Cello KE, Johnson CA, Anderson DR, Gordon MO, Kass MA. Longitudinal and cross-sectional analyses of visual field progression in participants of the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2010 Dec; 128(12):1528-32. PMID: 21149774; PMCID: PMC3914151.
    17. Choi SS, Zawadzki RJ, Lim MC, Brandt JD, Keltner J, Doble N, Werner JS. Evidence of outer retinal changes in glaucoma patients as revealed by ultrahigh-resolution in vivo retinal imaging. Br J Ophthalmol. 2011 Jan; 95(1):131-41. PMID: 20956277; PMCID: PMC3020908.
    18. Keltner J, Johnson CA, Cello KE, Dontchev M, Gal RL, Beck RW. Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years. Arch Ophthalmol. 2010 Mar; 128(3):330-7. PMID: 20212204; PMCID: PMC4107874.
    19. Kupersmith MJ, Miller N, Balcer L, Gordon L, Wall M, Keltner J, Friedman D, Feldon S, McDermott M, Kieburtz K. The Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC). J Neuroophthalmol. 2009 Sep; 29(3):259-61. PMID: 19726952.
      View in: PubMed
    20. Kashii S, Keltner J. New international classification of diseases (ICD-11) needs NANOS input. J Neuroophthalmol. 2009 Jun; 29(2):162. PMID: 19491651.
      View in: PubMed
    21. Oyama Y, Burt RK, Thirkill C, Hanna E, Merrill K, Keltner J. A case of autoimmune-related retinopathy and optic neuropathy syndrome treated by autologous nonmyeloablative hematopoietic stem cell transplantation. J Neuroophthalmol. 2009 Mar; 29(1):43-9. PMID: 19458576.
      View in: PubMed
    22. Choi SS, Zawadzki RJ, Greiner MA, Werner JS, Keltner J. Fourier-domain optical coherence tomography and adaptive optics reveal nerve fiber layer loss and photoreceptor changes in a patient with optic nerve drusen. J Neuroophthalmol. 2008 Jun; 28(2):120-5. PMID: 18562844; PMCID: PMC2584152.
    23. Choi SS, Zawadzki RJ, Keltner J, Werner JS. Changes in cellular structures revealed by ultra-high resolution retinal imaging in optic neuropathies. Invest Ophthalmol Vis Sci. 2008 May; 49(5):2103-19. PMID: 18436843; PMCID: PMC2707837.
    24. Huang CQ, Carolan J, Redline D, Taravati P, Woodward KR, Johnson CA, Wall M, Keltner J. Humphrey Matrix perimetry in optic nerve and chiasmal disorders: comparison with Humphrey SITA standard 24-2. Invest Ophthalmol Vis Sci. 2008 Mar; 49(3):917-23. PMID: 18326712.
      View in: PubMed
    25. Taravati P, Woodward KR, Keltner J, Johnson CA, Redline D, Carolan J, Huang CQ, Wall M. Sensitivity and specificity of the Humphrey Matrix to detect homonymous hemianopias. Invest Ophthalmol Vis Sci. 2008 Mar; 49(3):924-8. PMID: 18326713.
      View in: PubMed
    26. Keltner J, Johnson CA, Cello KE, Bandermann SE, Fan J, Levine RA, Kass MA, Gordon MO. Visual field quality control in the Ocular Hypertension Treatment Study (OHTS). J Glaucoma. 2007 Dec; 16(8):665-9. PMID: 18091452.
      View in: PubMed
    27. Gerth C, Zawadzki RJ, Choi SS, Keltner J, Park SS, Werner JS. Visualization of lipofuscin accumulation in Stargardt macular dystrophy by high-resolution Fourier-domain optical coherence tomography. Arch Ophthalmol. 2007 Apr; 125(4):575. PMID: 17420386.
      View in: PubMed
    28. Keltner J, Fine SL, Abrams GW, Mondino B. Subspecialty fellowships: standardizing and enhancing the educational experience. Ophthalmology. 2007 Apr; 114(4):628.e1-3. PMID: 17320965.
      View in: PubMed
    29. Sanchez RN, Smith AJ, Carelli V, Sadun AA, Keltner J. Leber hereditary optic neuropathy possibly triggered by exposure to tire fire. J Neuroophthalmol. 2006 Dec; 26(4):268-72. PMID: 17204920.
      View in: PubMed
    30. Levine RA, Demirel S, Fan J, Keltner J, Johnson CA, Kass MA. Asymmetries and visual field summaries as predictors of glaucoma in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci. 2006 Sep; 47(9):3896-903. PMID: 16936102; PMCID: PMC1995656.
    31. Keltner J, Johnson CA, Anderson DR, Levine RA, Fan J, Cello KE, Quigley HA, Budenz DL, Parrish RK, Kass MA, Gordon MO. The association between glaucomatous visual fields and optic nerve head features in the Ocular Hypertension Treatment Study. Ophthalmology. 2006 Sep; 113(9):1603-12. PMID: 16949445.
      View in: PubMed
    32. Choi SS, Doble N, Hardy JL, Jones SM, Keltner J, Olivier SS, Werner JS. In vivo imaging of the photoreceptor mosaic in retinal dystrophies and correlations with visual function. Invest Ophthalmol Vis Sci. 2006 May; 47(5):2080-92. PMID: 16639019; PMCID: PMC2583223.
    33. Keltner J, Johnson CA, Levine RA, Fan J, Cello KE, Kass MA, Gordon MO. Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2005 Sep; 123(9):1201-6. PMID: 16157799; PMCID: PMC1828122.
    34. Anderson AJ, Johnson CA, Fingeret M, Keltner J, Spry PG, Wall M, Werner JS. Characteristics of the normative database for the Humphrey matrix perimeter. Invest Ophthalmol Vis Sci. 2005 Apr; 46(4):1540-8. PMID: 15790927; PMCID: PMC2581814.
    35. Beck RW, Smith CH, Gal RL, Xing D, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner J, Kupersmith MJ, Miller NR, Moke PS, Nazarian S, Orengo-Nania S, Savino PJ, Shults WT, Trobe JD, Wall M. Neurologic impairment 10 years after optic neuritis. Arch Neurol. 2004 Sep; 61(9):1386-9. PMID: 15364684.
      View in: PubMed
    36. Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner J, Kupersmith MJ, Miller NR, Moke PS, Nazarian S, Orengo-Nania S, Savino PJ, Shults WT, Smith CH, Trobe JD, Wall M, Xing D. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004 Jan; 137(1):77-83. PMID: 14700647.
      View in: PubMed
    37. Beck RW, Trobe JD, Moke PS, Gal RL, Xing D, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner J, Kupersmith MJ, Miller NR, Nazarian S, Orengo-Nania S, Savino PJ, Shults WT, Smith CH, Wall M. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003 Jul; 121(7):944-9. PMID: 12860795.
      View in: PubMed
    38. Keltner J, Johnson CA, Cello KE, Edwards MA, Bandermann SE, Kass MA, Gordon MO. Classification of visual field abnormalities in the ocular hypertension treatment study. Arch Ophthalmol. 2003 May; 121(5):643-50. PMID: 12742841.
      View in: PubMed
    39. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner J, Miller JP, Parrish RK, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun; 120(6):701-13; discussion 829-30. PMID: 12049574.
      View in: PubMed
    40. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner J, Miller JP, Parrish RK, Wilson MR, Kass MA. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun; 120(6):714-20; discussion 829-30. PMID: 12049575.
      View in: PubMed
    41. Johnson CA, Keltner J, Cello KE, Edwards M, Kass MA, Gordon MO, Budenz DL, Gaasterland DE, Werner E. Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology. 2002 Mar; 109(3):432-7. PMID: 11874743.
      View in: PubMed
    42. Gerth C, Garcia SM, Ma L, Keltner J, Werner JS. Multifocal electroretinogram: age-related changes for different luminance levels. Graefes Arch Clin Exp Ophthalmol. 2002 Mar; 240(3):202-8. PMID: 11935277; PMCID: PMC2570348.
    43. Keltner J, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol. 2001 Sep; 21(3):173-87. PMID: 11725182.
      View in: PubMed
    44. Keltner J, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO. Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group. Arch Ophthalmol. 2000 Sep; 118(9):1187-94. PMID: 10980763.
      View in: PubMed
    45. Keltner J, Johnson CA, Spurr JO, Beck RW. Comparison of central and peripheral visual field properties in the optic neuritis treatment trial. Am J Ophthalmol. 1999 Nov; 128(5):543-53. PMID: 10577521.
      View in: PubMed